Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Imbruvica
Pharma
As Imbruvica fails, Brukinsa wins FDA nod in follicular lymphoma
With the first follicular lymphoma nod for a BTK inhibitor, BeiGene's Brukinsa will go up against CAR-T cell therapies and bispecifics.
Angus Liu
Mar 7, 2024 4:08pm
An Imbruvica combo regimen could have a new future in MCL
Dec 12, 2023 12:33pm
Lilly's Jaypirca blazes CLL trail with FDA approval
Dec 4, 2023 4:11am
Imbruvica takes $2.1B hit with CMS negotiations, AbbVie says
Oct 27, 2023 11:51am
AbbVie's Imbruvica-Brukinsa patent suit may have merit: expert
Jun 27, 2023 10:48am
AbbVie sues BeiGene over brand-new Imbruvica patent
Jun 15, 2023 10:35am